Order Article Reprints

Stege H, Haist M, Schultheis M, Fleischer MI, Mohr P, Meier F, Schadendorf D, Ugurel S, Livingstone E, Zimmer L, et al. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study. Cancers. 2021; 13(10):2312. https://doi.org/10.3390/cancers13102312

Stege, Henner, Maximilian Haist, Michael Schultheis, Maria Isabel Fleischer, Peter Mohr, Friedegund Meier, Dirk Schadendorf, Selma Ugurel, Elisabeth Livingstone, Lisa Zimmer, and et al. 2021. "Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study" Cancers 13, no. 10: 2312. https://doi.org/10.3390/cancers13102312

Stege, H., Haist, M., Schultheis, M., Fleischer, M. I., Mohr, P., Meier, F., Schadendorf, D., Ugurel, S., Livingstone, E., Zimmer, L., Herbst, R., Pföhler, C., Kähler, K., Weichenthal, M., Terheyden, P., Nashan, D., Debus, D., Kaatz, M., Ziller, F., ... Loquai, C. (2021). Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study. Cancers, 13(10), 2312. https://doi.org/10.3390/cancers13102312